Anebulo Pharmaceuticals (NASDAQ:ANEB) Releases Earnings Results, Beats Expectations By $0.08 EPS

Anebulo Pharmaceuticals (NASDAQ:ANEB) posted its earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Stock Down 2.6 %

Shares of Anebulo Pharmaceuticals stock traded down $0.05 during trading hours on Friday, hitting $1.91. The company’s stock had a trading volume of 3,269 shares, compared to its average volume of 6,842. The business has a fifty day moving average of $2.05 and a 200 day moving average of $2.35. Anebulo Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $3.61. The company has a market capitalization of $49.53 million, a PE ratio of -5.30 and a beta of -1.01.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.